MacroGenics Inc. (MGNX)
NASDAQ: MGNXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MGNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $226.14M
- EPS (TTM)
- -$1.70
- Dividend yield
- None
- 52-week range
- 1.29 – 5.08
- Day range
- 3.53 – 3.73
- Volume / Avg
- 509.63K / 623.51K
- Beta
- —
- Shares outstanding
- 63.70M
- Next earnings
- Nov 12, 2026
52-week range
MGNX stock today
Shares of MacroGenics (MGNX) finished lower on Oct 7 at $3.55, a drop of 2.47% or $0.09 per share, versus the S&P 500's 0.22% decline. At this level, MGNX sits in the middle of its 52-week range of $1.29 to $5.08: 30.1% below the high, set on Jun 24, 2026 and 175.2% above the low. MGNX is up 120.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 106.4%.
MacroGenics has posted a net loss over the last twelve months (EPS of -$1.70), so its P/E ratio is not meaningful. MacroGenics's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About MacroGenics
Company profileMacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Eric Blasius Risser
- Headquarters
- Rockville, MD
- Employees
- 293
- IPO year
- 2013
- Website
- macrogenics.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$8.00+125.35%
- Strong buy 1
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
MacroGenics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs MGNX |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs MGNX |
| IFRXInflaRx N.V. | 1.56 | -1.27% | $229.89M | vs MGNX |
| KROSKeros Therapeutics Inc. | 11.21 | +1.82% | $222.26M | vs MGNX |
| PRQRProQR Therapeutics N.V. | 1.63 | -1.21% | $230.02M | vs MGNX |
| IPSCCentury Therapeutics Inc. | 1.28 | -3.03% | $231.78M | vs MGNX |
| TRDAEntrada Therapeutics Inc. | 5.61 | +3.51% | $218.43M | vs MGNX |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.71 | -0.73% | $218.35M | vs MGNX |
Indexes, lists and sector
Appears in lists
MacroGenics stock FAQ
What is MacroGenics's stock price today?
MGNX last traded at $3.55 as of Oct 7, 4:00 PM EDT, down 2.47% on the day. Prices are delayed at least 15 minutes.
When is MacroGenics's next earnings date?
MacroGenics is expected to report earnings on Thursday, November 12, 2026.
Who is MacroGenics's CEO?
Mr. Eric Blasius Risser is the chief executive officer of MacroGenics Inc., which has about 293 employees.
What is the MGNX 52-week high?
The 52-week high for MGNX is $5.08 and the 52-week low is $1.29. The stock is currently 30.1% below its high.